|
|
|
|
Development and characterization of temozolomide resistant glioma cell line by pulse exposure |
|
XIANG Ding-chao1, WANG Cun-zu2, LU Xiao-feng1, OUYANG Qi3 |
(1.School of Clinical Medicine, Jiangsu University, Zhenjiang Jiangsu 212001; 2.Department of Neurosurgery, Northern Jiangsu People,s Hospital, Yangzhou Jiangsu 225001; 3.School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang Jiangsu 212013, China) |
|
|
|
|
Abstract Objective: To build temozolomide resistant glioma cell line in vitro, and to investigate its biological characteristics. Methods: By using pulse exposure to induce and build resistant to temozolomide(TMZ) human glioma U251 cell lines (named U251／TMZ); MTT was applied to detect the sensitivity of the parental cells (U251) and U251／TMZ to TMZ; drew proliferation curves of both cells and their growing conditions were compared; immunofluorescence technique was applied to detect CD133 expression; western blot assay was applied to detect the ABCG2 expression of both cells. Results: Temozolomide resistant glioma cell line had been successfully constructed and the resistance index of U251／TMZ was 8.1 times (t=-63.28,P=0.00) as high as parental cells; the proliferation U251／TMZ was slower than that of parental cells; by applying immunofluorescence assay to detect CD133 expression, there was a significant increase in U251／TMZ compared with parental cells(t=45.35,P=0000); by applying western blot assay to detect ABCG2 expression, it was found that U251／TMZ was significantly higher than pro-generation(t=6.19,P=0.00). Conclusion: The U251／TMZ developed with the method of pulse exposure displayed a certain amount of resistance, and possessed obvious biological characteristics of glioma stem cells.
|
|
Received: 22 October 2012
|
|
|
|
| [1] Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets［J］. Cancer Chemother Pharmacol,2009,64(4):647-655.［2］ Tabatabai G, Weller M. Glioblastoma stem cells［J］. Cell Tissue Res,2011,343(3):459-465.［3］ 杨伟现,向定朝,王存祖,等. 替莫唑胺化疗对胶质瘤U251中CD133+细胞的影响［J］. 江苏医药,2012,38(10): 1124-1127.［4］ Yang LY, Trujillo JM. Biological characterization of multidrug-resistant human colon carcinoma sublines induced／selected by two methods［J］. Cancer Res,1990,50(11):3218-3225.［5］ 邵泽勇,沈鼎明,伍烽,等. 两种方法建立的人肝癌细胞多药耐药模型的比较［J］. 肿瘤,2005,25(1):51-54［6］ Mclendon RE, Rich JN. Glioblastoma Stem Cells: A Neuropathologist′s View［J］. J Oncol,2011,2011:397195.［7］ 宗志涛,黄燕,于军. 胶质瘤耐药机制研究进展［J］. 山东医药,2011,51(2):111-112［8］ 孙国臣,许百男,马晓东. 脑胶质瘤化疗耐药机制的研究进展［J］. 临床军医杂志,2011,39(2):392-394. |
|
|
|
2013, Vol. 23 
